Pyxis Oncology Stock Revenue
| PYXS Stock | USD 2.10 1.72 45.03% |
Pyxis Oncology fundamentals help investors to digest information that contributes to Pyxis Oncology's financial success or failures. It also enables traders to predict the movement of Pyxis Stock. The fundamental analysis module provides a way to measure Pyxis Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pyxis Oncology stock.
| Last Reported | Projected for Next Year |
Pyxis | Revenue |
Pyxis Oncology Company Revenue Analysis
Pyxis Oncology's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Pyxis
Projected quarterly revenue analysis of Pyxis Oncology provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Pyxis Oncology match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Pyxis Oncology's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Pyxis Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Pyxis Oncology reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Pyxis Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pyxis Oncology's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pyxis Oncology could also be used in its relative valuation, which is a method of valuing Pyxis Oncology by comparing valuation metrics of similar companies.Pyxis Oncology is currently under evaluation in revenue category among its peers.
Pyxis Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pyxis Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pyxis Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Pyxis Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Pyxis Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pyxis Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pyxis Oncology's value.| Shares | State Street Corp | 2024-06-30 | 742.9 K | Perceptive Advisors Llc | 2024-09-30 | 508.5 K | Boothbay Fund Management, Llc | 2024-06-30 | 492.5 K | Superstring Capital Management Lp | 2024-06-30 | 484.4 K | Northern Trust Corp | 2024-09-30 | 394 K | Hillhouse Capital Advisors, Ltd. | 2024-06-30 | 382.6 K | Decheng Capital Llc | 2024-06-30 | 326.8 K | Bank Of New York Mellon Corp | 2024-06-30 | 311.6 K | Bridgeway Capital Management, Llc | 2024-06-30 | 246.5 K | Deep Track Capital, Lp | 2024-09-30 | 4.2 M | Laurion Capital Management Lp | 2024-06-30 | 3.9 M |
Pyxis Fundamentals
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (3.99) % | ||||
| Current Valuation | 600.03 K | ||||
| Shares Outstanding | 59.47 M | ||||
| Shares Owned By Insiders | 24.54 % | ||||
| Shares Owned By Institutions | 54.50 % | ||||
| Number Of Shares Shorted | 5.86 M | ||||
| Price To Book | 0.81 X | ||||
| Price To Sales | 7.73 X | ||||
| EBITDA | (78.49 M) | ||||
| Net Income | (73.79 M) | ||||
| Cash And Equivalents | 223.36 M | ||||
| Cash Per Share | 7.48 X | ||||
| Total Debt | 21.33 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 15.19 X | ||||
| Book Value Per Share | 2.58 X | ||||
| Cash Flow From Operations | (70.71 M) | ||||
| Short Ratio | 10.78 X | ||||
| Earnings Per Share | (1.06) X | ||||
| Price To Earnings To Growth | 0.01 X | ||||
| Target Price | 10.67 | ||||
| Number Of Employees | 54 | ||||
| Beta | 1.28 | ||||
| Market Capitalization | 124.88 M | ||||
| Total Asset | 173.73 M | ||||
| Retained Earnings | (286.23 M) | ||||
| Working Capital | 98.84 M | ||||
| Net Asset | 173.73 M |
About Pyxis Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pyxis Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pyxis Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pyxis Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.